Role of psilocybin in the treatment of depression

Therapeutic Advances in Psychopharmacology

Volumn 7, Issue 1, 2017, Pages 54-56

  Mahapatra, Ananya ^a   Gupta, Rishi ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

depression; hallucinogen; psilocybin; treatment

Indexed keywords

PSILOCYBINE;

ANXIETY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FUNDING; HUMAN; LETTER; MAJOR DEPRESSION; MEDICAL RESEARCH; RISK BENEFIT ANALYSIS; RISK FACTOR; TREATMENT INDICATION;

EID: 85018923597     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125316676092     Document Type: Letter

References (21)

1. Carhart-Harris R., Bolstridge M., Rucker J., Day C., Erritzoe D., Kaelen M.. (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3: 619–627.
2. Carhart-Harris R., Erritzoe D., Williams T., Stone J., Reed L., Colasanti A.. (2012a) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A 109: 2138–2143.
3. Carhart-Harris R., Leech R., Williams T., Erritzoe D., Abbasi N., Bargiotas T.. (2012b) Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. Br J Psychiatry 200: 238–244.
4. Dakwar E., (2016) The death and rebirth of hallucinogens. Drug Alcohol Depend 165: 293–297.
5. DeRubeis R., Siegle G., Hollon S., (2008) Cognitive therapy versus medication for depression: treatment outcomes and neural mechanisms. Nat Rev Neurosci 9: 788–796.
6. Geyer M., Nichols D., Vollenweider F., (2009) Serotonin-related psychedelic drugs. In: Squire L., (ed.), Encyclopedia of Neuroscience. Oxford: Academic Press.
7. Gonzalez-Maeso J., Weisstaub N., Zhou M., Chan P., Ivic L., Ang R.. (2007) Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53: 439–452.
8. Griffiths R., Richards W., McCann U., Jesse R., (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacol (Berl) 187: 268–283.
9. Griffiths R., Richards W., Johnson M., McCann U., Jesse R., (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol 22: 621–632.
10. Grob C., Danforth A., Chopra G., Hagerty M., McKay C., Halberstadt A.. (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68: 71–78.
11. Holtzheimer P., Mayberg H., (2011) Stuck in a rut: rethinking depression and its treatment. Trends Neurosci 34: 1–9.
12. Johansen P., Krebs T., (2015) Psychedelics not linked to mental health problems or suicidal behavior: a population study. J Psychopharmacol 29: 270–279.
13. Kraehenmann R., Preller K., Scheidegger M., Pokorny T., Bosch O., Seifritz E.. (2015a) Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry 78: 572–581.
14. Kraehenmann R., Schmidt A., Friston K., Preller K., Seifritz E., Vollenweider F., (2015b) The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. NeuroImage Clin 11: 53–60.
15. Krebs T., Johansen P., (2013) Psychedelics and mental health: a population study. PLoS One 8: e63972.
16. Osório Fde L., Sanches R., Macedo L., Santos R., Maia-de-Oliveira J., Wichert-Ana L.. (2015) Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Rev Bras Psiquiatr 37: 13–20.
17. Sanches R., de Lima Osório F., dos Santos R., Macedo L., Maia-de-Oliveira J., Wichert-Ana L.. (2016) Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression. J Clin Psychopharmacol 36: 77–81.
18. Studerus E., Kometer M., Hasler F., Vollenweider F., (2011) Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol 25: 1434–1452.
19. Tylš F., Paleniček T., Horaček J., (2014) Psilocybin – summary of knowledge and new perspectives. Eur Neuropsychopharmacol 24: 342–356.
20. 2A and 5-HT2C receptors and their atypical regulation properties. Life Sci 72: 2429–2449.
21. Vollenweider F., Kometer M., (2010) The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 11: 642–651.